Invasive mycoses represent a rare but severe complication following hemopoietic SCT (HSCT) in children. Their incidence is related to the type of donor, being higher after allogeneic transplant, especially from alternative donors. Moreover, the incidence of invasive mycoses varies in the different post transplant phases. Neutropenia, lymphopenia, GvHD, high-dose steroids or other immunosuppressive drugs represent well-known risk factors. The clinical features of invasive mycoses after HSCT in children are similar to those observed in adults, and the diagnostic tools, including Aspergillus galactomannan antigen detection, are feasible also in pediatrics. Mortality due to invasive mycoses after HSCT in children is high.
Introduction
The number of patients undergoing potentially life-saving chemotherapy for neoplastic diseases has increased quite dramatically in recent years; unfortunately, so has the incidence of life-threatening invasive fungal infections (IFI) occurring in these patients. This is especially true for recipients of bone marrow transplants. Based on autopsy studies, it appears that the successful outcome of up to onequarter of all BMTs carried out may be jeopardized by such infections. Questions of how to manage such patients remain problematic, for several reasons. First, it is frequently difficult to confirm a fungal infection until late in the course of the disease; second, some organisms have intrinsic or acquired resistance to antifungal agents; third, there is a risk of renal and other drug-related toxicity, particularly in BMT patients receiving concomitant therapy for GvHD; and finally, all therapeutic and prophylactic efforts can be frustrated by the absolute inability of the patient to produce an adequate immunological response. In this article, we will try to review the most important issues related to epidemiology and management of fungal infections in HSCT recipients, focusing as much as possible on pediatric data.
Epidemiology and risk factors for IFI after HSCT
The epidemiology of IFI varies according to the type of donor and the time elapsed from the transplant.
1
In autologous HSCT recipients, the highest frequency of IFI is observed during the pre-engraftment period, [1] [2] [3] whereas in allogeneic HSCT, the incidence of IFI is reported to be bimodal, with two peaks: the first during the pre-engraftment period and the other after 3-4 months from the procedure. 2, 3 In the pre-engraftment period, IFI is reported in less that 5% of the procedures. 2 Granulocytopenia, mucositis and the presence of indwelling central venous catheters are the most important risk factors. Candida species, mainly acquired through the gastrointestinal tract or the skin through central catheters, are the major causes of IFI during this period, 4 but the administration of fluconazole prophylaxis has drastically reduced their incidence. In this setting, aspergillosis has become the most common cause of early fungal infection, with a peak at 2-3 weeks after HSCT. In this period, invasive aspergillosis is probably due to the reactivation of a pre-existing infection acquired before the transplant procedure. Near one-third of patients with a previous IFI may reactivate the infection in the post transplant period, and in this case, mortality is very high. 5, 6 Primary colonization and infection by Aspergillus are a rare event in the early post transplant periods. In fact, since Aspergillus is inhaled through the respiratory tract, the use of HEPA air filtration in all HSCT units reduces the risk of acquisition of this pathogen. However, Aspergillus has been discovered in hospital water supplies as well, thus explaining the presence of cases of invasive aspergillosis even in wards equipped with effective air filtration systems.
In the late post-engraftment period invasive mycoses represent an important cause of morbidity and mortality mainly in allogeneic HSCT, 8 with an incidence that varies from 10 to 15% 2 and a peak after 3-4 months from the procedure. 3 However, some cases are reported even many months (or years) later, 2,9-11 in the presence of persistent immunosuppression.
Many factors, frequently present both in concomitance and in sequence in the same patient, have been indicated as determining the risk of this complication. The administration of corticosteroids at dose 41 mg/kg/day of prednisone (or equivalents) for a period longer than 7 days in a patient with GvHD probably represents the most frequently reported risk factor. 2 The use of monoclonal antibodies for treatment of refractory forms of GvHD may represent a 'new,' additional important risk factor, acting by means of a combined (T-and B-cell) profound and prolonged disruption of immunity. 12 Data regarding invasive mycoses in children are scanty. Five studies published between 2000 and 2006, [13] [14] [15] [16] [17] reported an incidence of IFI that varied from 1 to 13% for yeast and from 3 to 14% for molds (Table 1) , with a higher incidence in allogeneic HSCT, especially from unrelated donors.
14 In a recent prospective Italian survey of invasive mycoses in children with cancer, 18 no episode was observed after autologous HSCT, whereas 77% (17/22) of invasive mycoses observed after allogeneic HSCT occurred in children receiving transplant from an alternative donor and only 23% (5/22) after transplant from a matched related donor. These observations were similar to that obtained in a retrospective analysis of IFI in 267 allogeneic HSCT performed at Gaslini Children Hospital (GCH)-Genoa, Italy, where the overall incidence of invasive mycoses was 6% (8/131) after allogeneic HSCT from a matched related donor and 13% (18/136) after HSCT from an alternative donor (P ¼ 0.049) (EC and RH, personal observations). With regard to the changes in the epidemiology over time after transplant, Hovi et al. 16 reported a bimodal peak of IFI after allogeneic HSCT in children, with a higher frequency in the post-engraftment periods. However, this observation was not confirmed by more recent reports, in which the highest frequency of IFI was observed in the pre-engraftment period, 13, 15 even if some episodes were observed many months after transplant. Similarly, in the Italian survey on IFI in children with cancer, 18 the median interval between the transplant procedure and IFI was 34 days, with 12 (54%) episodes occurring before day 30 and 6 (27%) occurring after day 100 from the procedure. These observations were also confirmed by the retrospective analysis performed at GCH. In this study, the incidence and rates of IFI were different according with donor type, with highest values in the first 10 days after HSCT, gradually decreasing over time from the procedure ( Table 2) .
Prolonged and profound neutropenia, high-dose steroids, severe acute or chronic GvHD have all been documented as important predisposing conditions in pediatrics also. [13] [14] [15] 18 Moreover, lymphocytopenia has been recently suggested as another important risk factor for IFI in children with cancer or receiving HSCT, being present in the majority of episodes observed in non-neutropenic patients. 18 Finally, patients' age represents a clearly agerelated risk factor for invasive aspergillosis, 13 with higher incidence in patients aged more than 10 years. This fact may be easily understood if we consider that previous colonization is a necessary condition for the development of IFI. In this case, Candida is frequently acquired soon after birth, 19 while colonization by Aspergillus is agedependent, 20 and this may explain the age-related incidence of this complication.
Clinical features and diagnostic tools
Clinical features of IFI in children receiving HSCT are similar to those observed in adults. Candida represents the most frequent isolated pathogen among yeasts, and fungemia is the most frequent clinical condition, especially in the presence of a central venous catheter, whereas hepatosplenic candidiasis is very rarely reported, especially in the presence of fluconazole prophylaxis. 4, 21 Aspergillus is the most frequent cause of IFI due to filamentous fungi, and the respiratory tract is the most frequent site of infection, although disseminated diseases may occur. 2, 3, 18 Serial chest computed tomography is the method of choice for early detection of invasive pulmonary aspergillosis in neutropenic patients. [22] [23] [24] [25] [26] In these settings, the halosign represents the typical early computed tomography scan feature of invasive pulmonary mold infections. 26 In non-neutropenic subjects, the radiological features may be different, with the possible observation of aspecific nodules or even interstitial lesions. 27 Serum galactomannan (GM) antigen detection has been indicated as a serological test for the diagnosis of invasive aspergillosis in immunocompromised hosts. 28 However, this test is not recommended in children, in spite of the presence of studies reporting good performance in pediatrics, 29 maybe on the basis of some study showing a high false positive rate in pediatrics, especially following allogeneic HSCT. 30 We conducted a retrospective analysis of the performance of GM in children treated at GCH from 1999 to 2005 (CV, EC, ICAAC, 2006, San Francisco). The test was defined as positive when the GM index cut-off was X0.7 with a single test (static cutoff), or between 0.5 and 0.7 with at least two consecutive sera (dynamic cut-off), 31 and cases of IFI were classified according with internationally accepted criteria. 28 Table 3 reports on the results of GM test during 119 post-HSCT periods at risk. The test resulted false positive in 12/119 (10%) of cases, all after allogeneic HSCT. In 10 (83%) of 12 patients, the false positive results were associated with the administration of piperacillin-tazobactam. 32, 33 The remaining two patients did not receive drugs or food usually associated with false positivity, 30, 34, 35 and the false positive test was presumptively attributed to the presence of GvHD. 30, 35, 36 After allogeneic HSCT, the sensitivity of the test was 50%, the specificity 87%, the positive predictive value 29% and the negative predictive value 94%, with a 2% risk of missing a true infection by a negative test, considering a 10% prevalence of invasive aspergillosis as that observed in our center. These data underline the reliability of the GM test at least for the exclusion of an invasive aspergillosis in allogeneic HSCT in children, as well.
Mortality
Mortality is high in adults who develop IFI during antineoplastic chemotherapy, being reported in 40-45% of candidemias 37 and in 58% of invasive aspergillosis. 6 Among allogeneic HSCT, mortality is even higher, with rates ranging from 67 to more than 90%. 5, 6 In pediatrics, mortality associated with IFI is also high, but the rates are generally lower than those reported in adults. 18 Among children receiving allogeneic HSCT, former studies reported a 66% mortality, 16 although in more recent surveys mortality was reported to vary between 35 13 and 41%. 18 The availability of new antifungal drugs has improved the survival of cancer patients with IFI, even if the response rate after allogeneic HSCT is still disappointing-ranging from 13 to 40% at 12 weeks after the end of antifungal treatment. [38] [39] [40] Non-comparative studies suggested that combined antifungal therapy could improve survival, 41, 42 also in allogeneic HSCT recipients with IFI, 40, 43, 44 but this advantage is no more present after 1 year from the diagnosis of invasive mycosis. 45 Also, in children, combination therapy did not seem to improve the prognosis of IFI. 18 Similarly, a recent prospective survey of combined antifungal therapy published by the Italian Association of Pediatric Hematology and Oncology demonstrated that the long-term prognosis was influenced more by the type of underlying disease and the post HSCT status, 46 than by the type of antifungal therapy (single-agent or combined). At present, the positive effect of combined therapy for survival of IFI is not clearly confirmed and only prospective and randomized trials will allow a definitive response to this question. 47 In conclusion, great advances have been made in our ability to diagnose and manage IFIs in cancer patients, although several needs are still unmet. This is particularly true in the pediatric field, in which there is an urgent need of information about new drugs that are frequently used off label.
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